OUR PPP SRT Global Mental Health Summit Partnership in Negotiation 

 

Global Mental Health Summit – KRFI Private-Public Sector Partnership Secretariat Roundtable on Opioid Abatement Matching Funds

​

Purpose and Vision

​

The Global Mental Health Summit convenes a strategic Private-Public Sector Partnership (PPP) Secretariat Roundtable to mobilize national and in-state consortium in alignment with mental health security and substance use disorder prevention initiatives. The KRFI Secretariat’s mission is to build a collaborative infrastructure linking clinicians, researchers, policymakers, and private sector stakeholders in an evidence-based consortium promoting safe, legal, and medically supervised ibogaine therapy and other innovative treatments for addiction, trauma, and treatment-resistant mental health conditions.

Through coordinated education, policy engagement, and community partnership, this summit aims to foster sustainable frameworks that strengthen the nation’s capacity to address the opioid crisis while safeguarding mental health security at state, national, and global levels.

​

Background

Addressing the Opioid and Substance Abuse and Mental Health Crises

​

The opioid epidemic continues to devastate communities across the United States, leading to significant loss of life and overwhelming strain on public health systems. Recognizing the urgent need for innovation, the Global Mental Health Security Fund for the Opioid Abatement Matching Fund initiative seeks to catalyze collaboration between public commissions, state authorities, and private sector innovators. By uniting under the KRFI Secretariat, these partnerships can unlock novel pathways for prevention, treatment, and recovery — advancing the science and accessibility of ibogaine and psychedelic-assisted therapies as potential medical interventions for chemical dependency.

 

A Call to Action

​

The KRFI Global Mental Health PPP Secretariat invites private sector investors, corporate sponsors, and public agencies to join the fight for prevention and recovery. Together, we can match in-state Opioid Abatement Funds with private innovation capital, creating a new model for National Mental Health Security that values both human lives and sustainable community health systems.

​

By bridging the public and private sectors, the Secretariat’s initiative represents a national call to action — to honor those lost to the opioid pandemic, to empower those in recovery, and to forge a scientifically grounded, equitable, and enduring path toward healing.

​

The Public-Private Partnership (PPP) Opportunity

Public Sector Benefits

Public entities, including In-State Opioid Abatement Funds and Commissions, can leverage PPP models to:

•Allocate resources more efficiently across prevention, treatment, and recovery programs.

•Drive innovation through partnerships beyond traditional government channels.

•Promote transparency, accountability, and measurable impact through data-driven evaluation.

•Ensure timely, high-quality delivery of public health services that enhance resilience and community well-being.

 

Private Sector Benefits
Private industry participants — including pharmaceutical innovators, biotech firms, clinical research organizations, and health technology enterprises — can:

​

•Strengthen their leadership in health equity and corporate responsibility.

•Build networks across medical, academic, and policy sectors.

•Support development of GAP, GLP, GMP, and GCP-compliant facilities for ibogaine and related psychedelic compounds.

•Co-develop scalable models that match public opioid abatement funds with local investments for manufacturing, clinical research, and evidence-based deployment.

​

Strengthened Public-Private Partnerships (PPPs)
PPPs represent a cornerstone for the advancement of mental health infrastructure and opioid abatement initiatives. By aligning with the Opioid Abatement Matching Fund, private sponsors gain access to:

​

•Federal and state tax incentives through nonprofit donations and matching programs.

•Subsidized infrastructure development for mental health research, production, and clinical implementation.

•Regulatory and technological acceleration through cross-sector collaboration.

​

Technological and Industrial Advancements
Through partnerships emphasizing automation, data integration, and advanced bioprocessing, the Summit fosters excellence in manufacturing innovation. These advancements enhance quality assurance (QA/QC), purification, and delivery of enhanced prodrugs and CNS-targeted therapies — accelerating market readiness while maintaining global compliance standards.

​

Challenges and Policy Imperatives

​

•January 2026 NYS Ibogaine Research Bill in progress, the natural products and innovative biopharmaceutical sectors continue to face barriers across the bioprocessing value chain. Challenges include:

​

•High production and extraction costs.

•Complexity in QA/QC and regulatory compliance.

•Fragmented infrastructure for technology transfer and commercialization.

•The Global Mental Health Summit prioritizes policy dialogue to address these constraints through:

•Development of regulatory harmonization frameworks for natural and entheogenic compounds.

•Incentivization of domestic manufacturing and green bioprocessing technologies.

•Creation of federal innovation corridors for psychedelic, botanical, and mental health R&D.

​

Building the Foundation for National Mental Health Securities   

​

JOIN OUR CONSORTIUM MEMBERSHP

​​

 

The Global Mental Health Summit serves as a strategic platform for public and private stakeholders to advance the National Mental Health Securities Framework, integrating innovation, policy, and global cooperation. Through this initiative, the KRFI Secretariat seeks to catalyze coordinated action between government entities, academic institutions, and the private sector to address the intersecting crises of opioid dependency, trauma, and mental health disorders.

The Sponsorship and Membership Program enables industry leaders, philanthropies, and investors to participate in the establishment of a sustainable ecosystem that leverages biotechnology, ethnopharmacology, and advanced data infrastructure to achieve measurable impact across mental health systems worldwide.

​

 

Key Growth Drivers of the National Mental Health Securities Sector

Innovation in Psychedelic and Plant-Derived Therapeutics

Cutting-edge psychedelic research enterprises are pioneering treatments through the integration of genomics, traditional medicine, and entheogenic science. By recognizing plant-derived and indigenous knowledge systems as part of biological diversity, these companies contribute to both scientific innovation and biodiversity preservation.

Formation of Global Bio-Clusters and Research Hubs

The Global Mental Health Summit supports the creation of bio-clusters that connect world-class universities, clinical centers, and psychedelic research hubs. These clusters facilitate evidence-based innovation, translational research, and scalable implementation of advanced biomanufacturing and CNS delivery systems.